This activity is expired and is no longer available for CME credit.


Innovative Treatment Trends in Neovascular Age-related Macular Degeneration and Diabetic Retinopathy

Author(s)/Faculty: W. Lloyd Clark, MD; Michael S. Ip, MD
Release Date: 10/21/2020Expiration Date: 10/20/2021
Credit Type: CME / ABO MOCNumber of Credits: 0
Content Type: LectureProvider:
Visual outcomes in patients with neovascular age-related macular degeneration (nAMD) and diabetic retinopathy (DR) have been greatly enhanced through the integration of anti–vascular endothelial growth factor (VEGF) therapies into treatment protocols. In DR, early intervention with anti-VEGF therapies has demonstrated significant slowing of disease progression and a reduction in vision-threatening complications. In those patients with nAMD, significant visual acuity gains have been demonstrated, yet treatment burden often leads to reduced patient adherence, resulting in suboptimal outcomes. Dosing strategies aimed at extending the time between dosing intervals while maintaining early visual acuity gains are evolving. In this educational activity, experts in the field summarize newer anti-VEGF injection protocols that may improve the long-term management of DR and nAMD as well as examine real-world clinical data that report on patient-related and anatomical factors that influence outcomes in patients being treated for nAMD and DR.